Pancreatic Ductal Adenocarcinoma (mPDAC)
7
2
2
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (7)
OSCAR II STUDY - The ONCObind CTC Removal Study
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Study of a Polygenic Risk Score to Predict the Risk of Pancreatic Ductal Adenocarcinoma
Immunoparalysis After Pancreaticoduodenectomy
A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
How Does Pre-operative Biliary Drainage in Pancreatic Adenocarcinoma Affect Surgical Outcomes in Pancreatic Cancer Surgery
Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC